Emily Estrada

On August 6, 2026, the US Food and Drug Administration (FDA) granted accelerated approval to vusolimogene oderparepvec (Tudriqev; Replimune) plus

Ociperlimab plus tislelizumab failed to improve overall survival compared with pembrolizumab as first-line treatment for patients with stage III/IV non-small cell lung cancer and PD-L1 expression of ≥50%, leading to the phase 3 AdvanTIG-302...

According to results from the phase 1/2 BGB-11417-201 study, sonrotoclax monotherapy produced rapid and durable responses in patients with relapsed

Long-term results from the phase 3 FeDeriCa trial showed that the fixed-dose subcutaneous pertuzumab plus trastuzumab maintained efficacy comparable

Results from the phase 1b/2 BEGONIA trial showed clinical activity with first-line durvalumab plus paclitaxel in unresectable locally advanced or metastatic triple-negative breast cancer, while adding capivasertib or oleclumab provided no...

Results from a phase 1/2 trial showed that third-generation anti-CD30 CAR T-cell therapy achieved a 95.5% objective response rate (ORR) and durable

Five-year follow-up results from the pivotal phase 2 ELIANA trial demonstrated durable remissions and long-term survival with tisagenlecleucel in

Results from the phase 2 BilT-02 trial showed that maintenance rucaparib plus nivolumab did not meet the prespecified 4-month progression-free

Results from the phase 2 DART trial showed that definitive thoracic radiation therapy with concurrent and consolidative durvalumab met the prespecified

Final safety and patient-reported outcome data from the phase 3 TROPION-Breast01 trial showed that datopotamab deruxtecan was associated with fewer